cervical cancer
Conditions
Interventions
Observation Group:None
Sponsors
Nantong Tumor Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. patients signed an informed consent form, voluntarily enrolled in this study, and had the willingness and ability to cooperate with data collection in this study; 2. clinical diagnosis of cervical cancer; 3.First prescription of QL1706 at the time of inclusion in the study (whether or not to prescribe QL1706 is at the discretion of the supervising physician and is not affected by this study).
Exclusion criteria
Exclusion criteria: Inclusion in this study is prohibited if the patient has any of the following: 1. the patient is undergoing or has plans to enroll in a clinical interventional study; 2. Inability to understand the research nature of the study or failure to obtain informed consent; 3. other conditions that, in the judgment of the investigator, make inclusion in the study inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse event; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival,PFS;Overall survival,OS;Objective Response Rate,ORR; | — |
Countries
China
Contacts
Public ContactLu Yunyan; Wu Xia
Nantong Tumor Hospital
Outcome results
None listed